2,4-thiazolidinedione has been researched along with Cardiac Failure in 21 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In T2D patients with ischemic stroke, lobeglitazone reduced the risk of cardiovascular complications similar to that of pioglitazone without an increased risk of HF." | 8.31 | Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study. ( Baik, M; Jeon, J; Kim, J; Yoo, J, 2023) |
| "To compare the risks of hospitalization for heart failure (HHF) associated with sulfonylurea (SU), dipeptidyl peptidase-4 inhibitor (DPP-4i), and thiazolidinedione (TZD) as add-on medications to metformin (MET) therapy using the data of Korean adults with type-2 diabetes from the Korean National Health Insurance database." | 7.91 | Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study. ( Ha, KH; Kim, DJ; Kim, HC; Lee, H; Lee, JH; Lee, SJ, 2019) |
| "According to package inserts, metformin is contraindicated in diabetic patients receiving drug treatment for heart failure therapy, and thiazolidinediones are not recommended in diabetic patients with symptoms of advanced heart failure." | 7.72 | Metformin and thiazolidinedione use in Medicare patients with heart failure. ( Foody, JM; Havranek, EP; Inzucchi, SE; Krumholz, HM; Masoudi, FA; Setaro, JF; Wang, Y, 2003) |
| "In T2D patients with ischemic stroke, lobeglitazone reduced the risk of cardiovascular complications similar to that of pioglitazone without an increased risk of HF." | 4.31 | Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study. ( Baik, M; Jeon, J; Kim, J; Yoo, J, 2023) |
| "To compare the risks of hospitalization for heart failure (HHF) associated with sulfonylurea (SU), dipeptidyl peptidase-4 inhibitor (DPP-4i), and thiazolidinedione (TZD) as add-on medications to metformin (MET) therapy using the data of Korean adults with type-2 diabetes from the Korean National Health Insurance database." | 3.91 | Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study. ( Ha, KH; Kim, DJ; Kim, HC; Lee, H; Lee, JH; Lee, SJ, 2019) |
| "The aim of the present study was to assess the risk of overall mortality, coronary artery disease (CAD), and congestive heart failure (CHF) in patients with type 2 diabetes mellitus (T2DM) treated with metformin (MF) and an additional antidiabetic agent." | 3.83 | Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic. ( Kannan, S; Karafa, M; Matsuda, S; Pantalone, KM; Wells, BJ; Zimmerman, RS, 2016) |
| "According to package inserts, metformin is contraindicated in diabetic patients receiving drug treatment for heart failure therapy, and thiazolidinediones are not recommended in diabetic patients with symptoms of advanced heart failure." | 3.72 | Metformin and thiazolidinedione use in Medicare patients with heart failure. ( Foody, JM; Havranek, EP; Inzucchi, SE; Krumholz, HM; Masoudi, FA; Setaro, JF; Wang, Y, 2003) |
| "The incidence of obesity and type 2 diabetes mellitus (DM2) in the United States has been increasing dramatically over the past 15 years, and is now at epidemic proportions." | 2.42 | Cardiovascular implications of thiazolidinedione therapy. ( King, D; Lamb, RE, 2004) |
| "The first thiazolidinedione derivative drug for diabetes, troglitazone, was found to cause fatal hepatotoxicity, although it was judged as safe during the clinical trial." | 2.41 | [Evaluation of thiazolidinedione derivative drugs for safety]. ( Iwata, M; Kobayashi, M, 2001) |
| "Multicentre, randomized, clinical trials that included over 100 participants comparing antidiabetic agents with a placebo or a different antidiabetic agent and reporting major adverse cardiovascular events (MACEs), or primarily reporting heart failure, were searched in the PubMed, Embase and Cochrane databases." | 1.91 | Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials. ( Frias, JP; Lim, S; Sohn, M, 2023) |
| "A 50-year-old obese white man with type 2 diabetes presented with cardiogenic shock." | 1.32 | Thiazolidinedione-induced congestive heart failure. ( Cheng, AY; Fantus, IG, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (76.19) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Yoo, J | 1 |
| Jeon, J | 1 |
| Baik, M | 1 |
| Kim, J | 1 |
| Sohn, M | 1 |
| Frias, JP | 1 |
| Lim, S | 1 |
| Lee, SJ | 1 |
| Ha, KH | 1 |
| Lee, JH | 1 |
| Lee, H | 1 |
| Kim, DJ | 1 |
| Kim, HC | 1 |
| Arnold, SV | 1 |
| Inzucchi, SE | 2 |
| Echouffo-Tcheugui, JB | 1 |
| Tang, F | 1 |
| Lam, CSP | 1 |
| Sperling, LS | 1 |
| Kosiborod, M | 1 |
| Kannan, S | 1 |
| Pantalone, KM | 1 |
| Matsuda, S | 1 |
| Wells, BJ | 1 |
| Karafa, M | 1 |
| Zimmerman, RS | 1 |
| Michaelson, J | 1 |
| Tang, WH | 1 |
| Francis, GS | 1 |
| Hoogwerf, BJ | 1 |
| Young, JB | 1 |
| Masoudi, FA | 1 |
| Wang, Y | 1 |
| Setaro, JF | 1 |
| Havranek, EP | 1 |
| Foody, JM | 1 |
| Krumholz, HM | 1 |
| Kennedy, FP | 1 |
| Kermani, A | 1 |
| Garg, A | 1 |
| Malone, RM | 1 |
| DeWalt, DA | 1 |
| Pignone, MP | 1 |
| Ives, TJ | 1 |
| Giles, TD | 1 |
| Hollenberg, NK | 1 |
| Nesto, RW | 1 |
| Bell, D | 1 |
| Bonow, RO | 1 |
| Fonseca, V | 1 |
| Grundy, SM | 1 |
| Horton, ES | 1 |
| Le Winter, M | 1 |
| Porte, D | 1 |
| Semenkovich, CF | 1 |
| Smith, S | 1 |
| Young, LH | 1 |
| Kahn, R | 1 |
| Cheng, AY | 1 |
| Fantus, IG | 1 |
| Mikhail, NE | 1 |
| Wali, S | 1 |
| Cope, D | 1 |
| Lamb, RE | 1 |
| King, D | 1 |
| Wang, F | 1 |
| Vergara, C | 1 |
| Carabino, J | 1 |
| Desilets, A | 1 |
| Vasquez, R | 1 |
| Aguilar, D | 1 |
| Bozkurt, B | 1 |
| Pritchett, A | 1 |
| Petersen, NJ | 1 |
| Deswal, A | 1 |
| Kobayashi, M | 1 |
| Iwata, M | 1 |
6 reviews available for 2,4-thiazolidinedione and Cardiac Failure
| Article | Year |
|---|---|
Thiazolidinedione associated volume overload and pulmonary hypertension.
Topics: Aged; Blood Volume; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypertension, Pulmonar | 2008 |
The patient with diabetes mellitus and heart failure: at-risk issues.
Topics: Cardiac Output, Low; Coronary Artery Disease; Diabetes Mellitus; Endothelium, Vascular; Heart Failur | 2003 |
Considerations for management of fluid dynamic issues associated with thiazolidinediones.
Topics: Body Fluids; Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Di | 2003 |
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.
Topics: Edema; Heart Failure; Humans; Hypoglycemic Agents; Safety; Thiazolidinediones; Weight Gain | 2004 |
Cardiovascular implications of thiazolidinedione therapy.
Topics: Cardiovascular Diseases; Contraindications; Decision Trees; Diabetes Mellitus, Type 2; Edema; Heart | 2004 |
[Evaluation of thiazolidinedione derivative drugs for safety].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Edema; Heart Fa | 2001 |
15 other studies available for 2,4-thiazolidinedione and Cardiac Failure
| Article | Year |
|---|---|
Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Insulin | 2023 |
Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Lik | 2023 |
Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, C | 2019 |
Understanding Contemporary Use of Thiazolidinediones.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agen | 2019 |
Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
Topics: Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug T | 2016 |
Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure.
Topics: Adult; Aged; Ascites; Diabetes Complications; Diabetes Mellitus; Dilatation, Pathologic; Edema; Fema | 2003 |
Metformin and thiazolidinedione use in Medicare patients with heart failure.
Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Contraindications; Cross-Sectional Studies; Diabetes Co | 2003 |
Do thiazolidinediones cause congestive heart failure?
Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Pulmonary Edema; Thiazoles; T | 2003 |
Thiazolidinedione-associated congestive heart failure and pulmonary edema.
Topics: Aged; Cardiomyopathies; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Kidne | 2003 |
Diabetes drugs a problem in heart failure.
Topics: Diabetes Complications; Diabetes Mellitus; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Th | 2003 |
Is the tolerability of long-term thiazolidinedione therapy overstated?
Topics: Confounding Factors, Epidemiologic; Diabetes Complications; Heart Failure; Humans; Hypoglycemic Agen | 2003 |
Thiazolidinedione-induced congestive heart failure.
Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; S | 2004 |
Thiazolidinedione-associated congestive heart failure and pulmonary edema.
Topics: Diabetes Mellitus; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Heart Failure; Hum | 2004 |
Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Edema; Female; | 2004 |
The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure.
Topics: Aged; Ambulatory Care; Case-Control Studies; Confidence Intervals; Diabetes Mellitus; Dose-Response | 2007 |